ArticleClinical oral investigations2025
Cymbopogon citratus essential oil infused zinc oxide nanoparticles for eco-friendly anticariogenic action.
Article in Clinical oral investigations, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveDental caries is a prevalent oral health problem primarily driven by Streptococcus mutans. This study focused on the green synthesis of zinc oxide nanoparticles incorporated with Cymbopogon citratus essential oil (CEOZnONPs) and evaluated their anti-cariogenic efficacy against S. mutans. METHODOLOGY: CEOZnONPs were prepared by dropwise addition of essential oil into zinc acetate solution at 100 °C, pH 7, and 800 rpm with polysorbate 80 as emulsifier. The nanoparticles were characterized by UV-Vis spectroscopy, HR-TEM, zeta potential, XRD, and FTIR. Antibacterial activity was assessed using MIC/MBC, adherence, biofilm inhibition, EPS production, and acidogenesis assays. An in vivo Wistar rat caries model and cytotoxicity assay on HeLa cell lines further validated efficacy and safety.
resultsMorphological analysis revealed that CEOZnONPs were predominantly spherical and rod-shaped with an average particle size of 49 nm. Its antibacterial activity demonstrated a MIC of 5 µg/mL and MBC of 10 µg/mL, inhibiting adherence to tooth surfaces (85%-97%), biofilm formation, and EPS production. The antioxidant activity showed DPPH and ABTS radical scavenging of 65.28% and 75.24%, respectively. Acid production by S. mutans was significantly reduced following treatment, with pH shifting from 4.5 to 6.2. These findings were corroborated by an in vivo study, which showed a substantial reduction in S. mutans colonies in Wistar rats over five weeks. Furthermore, the CEOZnONPs (90 µg/mL) were also non-cytotoxic to HeLa cell lines.
conclusionThis study is the first to report the antibacterial and anti-cariogenic efficacy of CEOZnONPs, which introduces a significant therapeutic approach. It is environmentally friendly and highly effective in combating S. mutans and preventing dental caries, opening novel avenues for future oral treatments. CLINICAL RELEVANCE: This nano-herbal formulation offers a promising, biocompatible alternative to conventional antimicrobials, with the potential to revolutionize caries prevention strategies in clinical dentistry.
Indexed as
Identifiers
41247535What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.